Free Trial

Nordea Investment Management AB Has $1.74 Million Holdings in Hologic, Inc. $HOLX

Hologic logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Nordea Investment Management AB cut its Hologic (NASDAQ: HOLX) stake by 99.2% in Q4, selling 2,809,275 shares and leaving 23,325 shares valued at $1.739 million.
  • Hologic's latest quarter missed expectations with EPS of $1.04 vs. $1.09 forecast and revenue of $1.05B vs. $1.07B, and several brokers have downgraded the stock leaving a consensus Hold and a $78.42 target.
  • Institutional ownership is high at 94.73%; shares opened at $75.67 (near a one-year high of $75.75) and the company has a market cap of $16.89 billion with a P/E of 31.53.
  • MarketBeat previews top five stocks to own in May.

Nordea Investment Management AB trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 99.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,325 shares of the medical equipment provider's stock after selling 2,809,275 shares during the quarter. Nordea Investment Management AB's holdings in Hologic were worth $1,739,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Winnow Wealth LLC acquired a new position in shares of Hologic during the 3rd quarter worth approximately $26,000. Root Financial Partners LLC bought a new position in shares of Hologic during the third quarter worth approximately $27,000. SJS Investment Consulting Inc. raised its position in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 362 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 168.5% in the third quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 310 shares during the period. Finally, Loomis Sayles & Co. L P bought a new stake in shares of Hologic in the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Down 0.0%

Shares of HOLX opened at $75.67 on Friday. The firm has a 50 day simple moving average of $75.22 and a two-hundred day simple moving average of $73.29. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.75. The company has a market cap of $16.89 billion, a P/E ratio of 31.53, a P/E/G ratio of 2.25 and a beta of 0.73.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts' consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business posted $0.87 EPS. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on HOLX. Evercore downgraded Hologic from an "outperform" rating to an "in-line" rating and reduced their price target for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Weiss Ratings reiterated a "hold (c)" rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, Argus lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday, January 12th. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of "Hold" and a consensus target price of $78.42.

Get Our Latest Stock Report on Hologic

Hologic Company Profile

(Free Report)

Hologic, Inc NASDAQ: HOLX is a global medical technology company specializing in women's health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.

Featured Articles

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hologic Right Now?

Before you consider Hologic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.

While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines